Literature DB >> 7082353

Stimulation of rat liver 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity by o,p'-DDD.

P W Stacpoole, C E Varnado, D P Island.   

Abstract

To investigate the mechanism by which o'p'-DDD (2,2-bis [2-chlorphenyl-4-chlorophenyl]-1,1-dichloroethane; Mitotane) produces hypercholesterolemia in man, we studied the effect of the drug on hepatic 3-hydroxy-3-methylglutaryl-CoA reductase activity in reverse light-cycled rats. o,p'-DDD markedly stimulated reductase activity in vivo and in vitro in a dose-dependent manner. This effect was not associated with demonstrable adrenocortical toxicity or changes in plasma corticosterone concentrations. Thus o,p'-DDD may elevate circulating cholesterol levels in man by increasing endogenous cholesterol synthesis. In addition, the o,p'-DDD may elevate circulating cholesterol levels in man by increasing endogenous cholesterol synthesis. In addition, the o,p'-DDD-treated rat may serve as a useful model for testing other agents for the ability to suppress endogenous cholesterol synthesis and lower circulating cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082353     DOI: 10.1016/0006-2952(82)90474-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Medicinal plants in therapy.

Authors:  N R Farnsworth; O Akerele; A S Bingel; D D Soejarto; Z Guo
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

2.  Regulation of rat liver hydroxymethylglutaryl coenzyme A reductase by a new class of noncompetitive inhibitors. Effects of dichloroacetate and related carboxylic acids on enzyme activity.

Authors:  P W Stacpoole; H J Harwood; C E Varnado
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

3.  Evaluation of 9-cis retinoic acid and mitotane as antitumoral agents in an adrenocortical xenograft model.

Authors:  Zoltán Nagy; Kornélia Baghy; Éva Hunyadi-Gulyás; Tamás Micsik; Gábor Nyírő; Gergely Rácz; Henriett Butz; Pál Perge; Ilona Kovalszky; Katalin F Medzihradszky; Károly Rácz; Attila Patócs; Peter Igaz
Journal:  Am J Cancer Res       Date:  2015-11-15       Impact factor: 6.166

4.  Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma.

Authors:  Sarah Allegra; Soraya Puglisi; Chiara Borin; Francesco Chiara; Vittoria Basile; Anna Calabrese; Giuseppe Reimondo; Silvia De Francia
Journal:  Biomedicines       Date:  2022-08-03

5.  Mitotane-induced hyperlipidemia: a retrospective cohort study.

Authors:  Hassan Shawa; Ferhat Deniz; Hadil Bazerbashi; Mike Hernandez; Rena Vassilopoulou-Sellin; Camilo Jimenez; Mouhammed Amir Habra
Journal:  Int J Endocrinol       Date:  2013-11-14       Impact factor: 3.257

Review 6.  Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art.

Authors:  Rosa Maria Paragliola; Francesco Torino; Giampaolo Papi; Pietro Locantore; Alfredo Pontecorvi; Salvatore Maria Corsello
Journal:  Eur Endocrinol       Date:  2018-09-10

7.  Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer.

Authors:  Vittoria Basile; Soraya Puglisi; Anna Calabrese; Anna Pia; Paola Perotti; Alfredo Berruti; Giuseppe Reimondo; Massimo Terzolo
Journal:  Cancers (Basel)       Date:  2020-09-14       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.